MDGH logo no text

New medicines for lasting change

We’re tackling the world’s most challenging diseases so that communities can thrive around the world

ABOUT US

Medicines Development for Global Health Limited (MDGH UK) develops medicines for neglected diseases that primarily affect people living in poverty.

It is an affiliate of Medicines Development for Global Health (MDGH Australia), an independent biopharmaceutical company incorporated in Australia and registered as a charity with the Australian Charities and Not-for-Profits Commission.

OUR MISSION

MDGH’s mission is to address health inequity by putting new and improved medicines into the hands of people who need them most while its core expertise is in the development of medicines to rigorous regulatory standards.

The company was incorporated as a company limited by guarantee on 3 June 2015 and is now in the process of applying for registration as a charity with the UK Charities Commission. The sole member of the Company is MDGH Australia, and together have an active Collaboration Agreement to govern the relationship between the two entities.

One man giving pills to another man who is the holding pills in his right hand.
Where we work

MDGH consists of independent legal entities in the following countries which collaborate in pursuance of their mission

YOU ARE HERE
22 Dec 2020

United Kingdom

Medicines Development for Global Health Limited is an independent biopharmaceutical company incorporated on 3 June 2015 as a company limited by guarantee in the UK. It is in the process of applying for registration as a charity with the Charity Commission for England and Wales.

Australia flag icon in a circle
United Kingdom flag icon in a circle

Headquarters, Australia

Medicines Development for Global Health Limited is an independent biopharmaceutical company incorporated in Australia (Australian Company Number 116 977 523) and registered as a charity with the Australian Charities and Not-for-Profits Commission.

Visit website
United States flag icon in a circle

United States

Medicines Development for Global Health, Inc, was incorporated on 6 July 2021 as a nonprofit corporation. It is in the process of applying for registration as a tax-exempt 501(c)(3) public charity.

Visit website
OUR TEAM

Board of directors

Mark Sullivan, AO

Managing Director

Lime green plus icon

Kate Antrobus, MPA, CFA

Chair of the Board

Lime green plus icon

Michael Elliott, FRCP

Director

Lime green plus icon

Lorna Meldrum, PhD

Director

Lime green plus icon

Andrew Wilks, PhD

Director

Lime green plus icon
WHAT WE DO

Moxidectin

MDGH Australia holds the world-wide intellectual property rights to moxidectin for treating onchocerciasis (river blindness) and other human diseases.

Moxidectin was successfully registered with the US Food and Drug Administration (FDA) in 2018 for onchocerciasis for people aged 12 years and older.

We are now generating the additional data required to carry out community-directed treatment in endemic areas, through targeting World Health Organization (WHO) endorsement for use in river blindness treatment programs.

Moxidectin is also being developed by MDGH Australia for other parasitic diseases that are caused by parasitic worm species or ectoparasites. These include programmes in scabies, strongyloidiasis, lymphatic filariasis and soil-transmitted helminths where human clinical trials are currently underway. Moxidectin for head lice is an additional development program at MDGH Australia, currently in the pre-clinical, proof-of-concept stage.

In 2019 and 2021, the European & Developing Countries Clinical Trials Partnership (EDCTP) provided two substantial grants to Medicines Development for Global Health Limited and partners: €4.6m for additional clinical trials comparing efficacy and safety of single or annual and biannual moxidectin or ivermectin treatment (grant RIA2017NCT-1843 MoxiMultiDoseMod), and €2.8m for the development of a paediatric formulation of moxidectin MiniMox (grant RIA2019PD-2880 MiniMox). Both projects are part of the EDCTP2 Programme supported by the European Union.

Moxidectin icon showing 3 blue tablets

Moxidectin for accelerating onchocerciasis elimination

This project includes a paediatric dose-finding study, two phase 3b trials comparing efficacy and safety of single dose and annual and biannual doses of moxidectin or ivermectin treatment, and mathematical modelling of moxidectin and ivermectin based elimination strategies to support country policy decisions.

SEE PROJECT INFORMATION
Moxidectin icon showing 3 blue tablets

Moxidectin paediatric formulation

This project aims to develop and qualify a paediatric formulation of moxidectin suitable for children from one to three years of age, to determine an appropriate dose of the formulation for this age range and to assemble data for submission to the US FDA in support of adding the paediatric formulation to the US FDA prescribing information.

Website coming soon.

In 2020, MDGH Australia secured the global rights to CC-11050 (AMG 634) from Amgen, an investigational treatment that holds promise in tackling two challenging diseases: tuberculosis and leprosy type 2 reactions.

PIPELINE (GLOBAL SITE)

Latest UK news

CONTACT US

Our global offices

United Kingdom

Medicines Development for Global Health Limited
(Company number 09622645)
c/o BCS Windsor House,
Station Court, Station Road, Great Shelford,
Cambridge, Cambridgeshire
CB22 6NE, United Kingdom

CONTACT US

Headquarters, Australia

Medicines Development for Global Health Limited
ABN 7116 977 523, an Australian public company limited by guarantee registered under the Corporations Act 2001.
Level 1, 18 Kavanagh Street, Southbank,
Victoria 3006, Australia

VISIT WEBSITE

United states

Medicines Development for Global Health, Inc.
41 Watchung Plaza, Montclair, NJ. 07042

VISIT WEBSITE